An international consortium led by Isabelle Meyts (KU Leuven) and Stuart Tangye (Garvan Institute) has published its findings on COVID-19 outcomes in individuals with rare inherited immune disorders known as PIDs. Compared to the general population, these patients had similar disease outcomes, but they were more likely to need intensive care and their average age was lower.
"We wanted to find out the impact of SARS-CoV-2 infection one individuals with rare immune disorders known as primary immunodeficiencies (PIDs). This group of patients is assumed to be at risk of severe COVID-19 disease if infected with SARS-CoV-2. ...
